Cyxone is a lean company
Cyxone is a lean, virtual company focused on developing T20K against Multiple Sclerosis (MS). T20K has passed the research stage, which reduces the time to key value-added activities such as clinical trials.
T20K's effects in cell and animal studies suggest that the drug may become a breakthrough product for MS patients.
Cyxone is seeking a commercial partner that may accelerate clinical development and increase the company’s value. Cyxone also intends to develop new pharmacologically active cyclotides for major diseases such as rheumatoid arthritis which provides opportunities for long-term value creation.
VD Kjell Stenberg presenterar Cyxone på BioStock Live i Stockholm
- May 16, 2018 13:57 (CEST)
- April 23, 2018 14:14 (CEST)
- April 20, 2018 17:35 (CEST)
- April 10, 2018 11:43 (CEST)
- March 27, 2018 14:24 (CEST)